MedTrace Logo

The Effects of Honey on Febrile Neutropenia in Children With Acute Lymphoblastic Leukemia

NCT02272673 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2014-10-24

No results posted yet for this study

Summary

Febrile neutropenia (FN) is a common and serious side effect of chemotherapy. Current management of FN is expensive and may induce side effects. Honey is a natural substance produced by honeybees. It possesses antioxidant, antimicrobial and anticancer effects. In addition, honey is not expensive. The aim of this study was to evaluate the effects of 12-week honey consumption on children with acute lymphoblastic leukemia (ALL) particularly with regards of FN episodes. This randomized crossover clinical trial included 40 patients of both sexes, aged 2.5 to 10 years. They were randomized into two equal groups \[intervention to control (I/C) and control to intervention (C/I)\]. The dietary intervention was 12-week honey consumption in a dose of 2.5g//kg body weight per dose twice weekly.

Conditions

Interventions

DIETARY_SUPPLEMENT

Honey

The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ahmad A Hamed, Dr · Pediatric department, Faculty of Medicine, Ain Shams University

  • Sahar A Mohamed, Dr · Faculty of Medicine, El-Azhar University

  • Nouran A Hassanen, M.B.B.Ch · Pediatric department, Faculty of Medicine, Ain Shams University

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-08-31
Completion
2014-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02272673 on ClinicalTrials.gov